Loading clinical trials...
Loading clinical trials...
Phase I, Open-Label, Single-Center, Randomized, Study of the Safety and Efficacy of 0.5 mg and 2.0 mg Ranibizumab in Patients With Macular Edema Secondary to Perfused Central Retinal Vein Occlusion
Conditions
Interventions
Ranibizumab (Lucentis)
Locations
3
United States
California Retina Consultants
Bakersfield, California, United States
California Retina Consultants
Santa Barbara, California, United States
California Retina Consultants
Santa Maria, California, United States
Start Date
January 1, 2010
Primary Completion Date
June 1, 2012
Completion Date
June 1, 2013
Last Updated
December 12, 2013
NCT05476926
NCT04667910
NCT06708637
NCT03417401
NCT04812977
NCT02390245
Lead Sponsor
California Retina Consultants
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions